Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer

Ramalho, Susana; Andrade, Liliana Aparecida Lucci De Angelo; Filho, Cássio Cardoso; Natal, Rodrigo de Andrade; Pavanello, Marina; Ferracini, Amanda Canato; Sallum, Luis Felipe; Sarian, Luís Otávio; Derchain, Sophie

doi:10.1177/1010428318823988

Cited by 12 publications

(11 citation statements)

References 27 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The prognostic value of 172 protein biomarkers was evaluated by immunohistochemistry in 174 studies (Table 2). These markers are classified according to their biological functions, mainly including such functional pathways as EMT and metastasis [59][60][61][62][63][64][65][66][67][68][69][70][71], inflammation and immunity [72][73][74][75][76][77][78][79][80][81][82][83][84], antioxidant [85,86], angiogenesis [87][88][89][90][91][92][93][94][95][96][97][98][99], cell proliferation, migration and invasion [100][101][102][103][104]…”

Section: Tissue-based Prognostic Biomarkersmentioning

confidence: 99%

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Liu¹,

Wu²,

Wang³

2021

J. Cancer

View full text Add to dashboard Cite

Ovarian cancer is a serious threat to women's health; its early diagnosis rate is low and prone to metastasis and recurrence. The current conventional treatment for ovarian cancer is a combination of platinum and paclitaxel chemotherapy based on surgery. The recurrence and progression of ovarian cancer with poor prognosis is a major challenge in treatment. With rapid advances in technology, understanding of the molecular pathways involved in ovarian cancer recurrence and progression has increased, biomarker-guided treatment options can greatly improve the prognosis of patients. This review systematically discusses and summarizes existing and new information on prognostic factors and biomarkers of ovarian cancer, which is expected to improve the clinical management of patients and lead to effective personalized treatment.

show abstract

Section: Tissue-based Prognostic Biomarkersmentioning

confidence: 99%

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Liu¹,

Wu²,

Wang³

2021

J. Cancer

View full text Add to dashboard Cite

show abstract

“…MicroRNAs (miRs) represent a class of 21-23 nucleotides long small non-coding RNAs that can act as oncogenes (8) or tumor suppressors (9) in various types of cancer, including gastrointestinal (10), liver (11), pancreatic (12), ovarian (13), lung (14) and breast cancer (15). miRs can bind directly to the 3'-untranslated region (UTR) of target genes to negatively regulate protein expression (16).…”

Section: Introductionmentioning

confidence: 99%

miR‑519 regulates the proliferation of breast cancer cells via targeting human antigen�R

et al. 2019

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent types of cancer among women that leads to millions of deaths worldwide every year. The mechanisms of breast cancer pathogenesis remain unclear. It has been reported that aberrant expression of miR-519, is associated with breast cancer development; however, the effects of miR-519 on breast cancer cell proliferation remain unknown. Therefore, the present study aimed to determine whether miR-519 could regulate breast cancer cell proliferation. A total of 20 pairs of primary breast cancer and adjacent normal tissues were collected from patients with breast cancer. miR-519 expression level was determined by reverse transcription-quantitative polymerase chain reaction. Furthermore, miR-519 mimics or inhibitors were transfected into breast cancer MCF-7 cells in order to up-or downregulate miR-519 expression. Subsequently, human antigen R (HUR), BCL-2 and BAX protein levels were analyzed by western blotting. MCF-7 cell proliferation was assessed using MTT and colony formation assays. A luciferase assay was performed to verify whether miR-519 could directly bind to HUR mRNA. The results demonstrated that miR-519 expression level was lower in primary breast cancer tissues compared with adjacent normal tissues. Furthermore, miR-519 overexpression and downregulation inhibited and stimulated MCF-7 cell proliferation, respectively. In addition, the results from luciferase assay demonstrated that HUR was a target of miR-519. HUR overexpression could reverse the effect of miR-519 mimics on MCF-7 cell proliferation, whereas HUR silencing could rescue the effect of miR-519 inhibitors on MCF-7 cell proliferation. These findings suggested that miR-519 may regulate MCF-7 cell proliferation by targeting HUR.

show abstract

“…Also, the majority of involved studies were reported by authors in Asia (China, Japan, Taiwan, and South Korea), and the other studies were 1 from Canada, 3 from the USA, and 1 from Brazil. Moreover, 12 types of cancers including 3 ovarian cancers [5,7,9], 2 breast cancers [12,13], 1 osteosarcoma [16], 3 lung cancers [6,9,10], urological cancers (UC) which include 2 gallbladder carcinomas [17], 1 renal cancer [18], and 1 urothelial carcinoma [19], and gastrointestinal (GI) malignancies which include 1 gastric cancer [4], 2 HCCs [20,21], 1 esophageal cancer [22], 1 colorectal cancer [23], 1 pancreatic carcinoma [11], and 1 oral cell carcinoma [24] were evaluated in this meta-analysis. The total subjects registered were divided into high and low DDR groups based on the DDR measurement results.…”

Section: Literature Search and Data Characteristicsmentioning

confidence: 99%

“…DDRs are distributed in different organs; in solid tissues, DDR 1 is more expressed in epithelial cells, and DDR 2 is limited to mesenchymal cells [4]. Recently, studies have shown that the expression of DDRs upregulated in different types of malignancies such as hepatocellular carcinoma (HCC) [5,6], gastric cancer [4], ovarian cancer [5,7,8], lung cancer [6,9,10], pancreatic carcinoma [11], and breast cancer [12,13]. To the best of our knowledge, no systematic review and meta-analysis has been done to assess the relation between DDR expression and clinicopathologic features and prognostic value of DDRs in patients with different malignancies; so in this meta-analysis, we systematically pooled related published evidence to explain the prognostic significance of DDR expression in malignant tumors.…”

Section: Introductionmentioning

confidence: 99%

Prognostic and Clinicopathologic Significance of Discoidin Domain Receptors in Different Human Malignancies: A Meta-Analysis

Ferns

Shabanian

Abadi

et al. 2021

Gastrointest Tumors

View full text Add to dashboard Cite

Background: Discoidin domain receptors (DDRs) belong to the receptor tyrosine kinases family and are activated by different types of collagens, which play roles in various physiological processes. An abnormal expression of DDRs is reported in different types of cancers. Despite many reports about the association and roles of high DDR expression levels in cancers, the prognostic values of DDRs are still unclear. This meta-analysis was performed to evaluate the prognostic effect of DDRs in different tissue cancers. Method: A literature search was performed in several related databases to find eligible English articles. Based on our research, 20 appropriate studies with 2,602 patients were selected till October 5, 2020. The pooled hazard ratio (HR) with a corresponding 95% confidence interval (CI) was computed to evaluate the strength of correlation between DDRs and survival of cancer patients. Result: Pooling results showed that a high DDR expression was significantly associated with poorer overall survival (OS) (HR = 1.304, 95% CI 1.007–1.69, p = 0.04). Subgroup analysis based on cancer type revealed a significant link between a high DDR expression level and poor OS both in gastrointestinal (pooled HR = 1.78, 95% CI 1.214–2.624, p = 0.003) and urological cancers (pooled HR = 1.42, 95% CI 1.062–1.82, p = 0.018). Conclusion: Our meta-analysis results suggest that high DDRs expression has the potential to be used as a biomarker of poor prognosis in cancers.

show abstract

Role of discoidin domain receptor 2 (DDR2) and microRNA-182 in survival of women with high-grade serous ovarian cancer

Cited by 12 publications

References 27 publications

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer

miR‑519 regulates the proliferation of breast cancer cells via targeting human antigen�R

Prognostic and Clinicopathologic Significance of Discoidin Domain Receptors in Different Human Malignancies: A Meta-Analysis

Contact Info

Product

Resources

About